2024 International Prophylaxis Study Group (IPSG) Virtual Webinar was held on the 26th of November.

Karin Fijnvandraat is Professor of Pediatric Hematology at the University of Amsterdam and Director of the Hemophilia Treatment Center Amsterdam. She trained in Pediatrics and specialized in Pediatric Hematology at the University of Amsterdam. Her clinical focus is on hemophilia, allied bleeding disorders and sickle cell disease. In 2007 she initiated the international INSIGHT Consortium to enhance collaboration on non-severe hemophilia research among 34 hemophilia treatment centers in 10 European countries and Australia. Her research in hemophilia focusses on phenotypic heterogeneity and inhibitor development in mild hemophilia A. Furthermore, she contributed to many multicenter studies in hemophilia, von Willebrand disease, neonatal transfusion and sickle cell disease.

Dr. Paul Babyn is a member of the IPSG imaging subgroup with extensive experience in pediatric musculoskeletal radiology and the imaging of hemophilia. Recently retired, Dr. Babyn is a pediatric radiologist and former Department Head at the Hospital for Sick Children who has held several other notable prior administrative and academic positions throughout his career including most recently as Physician Executive of Provincial Programs at the Saskatchewan Health Authority and Professor and former Unified Head of the Department of Medical Imaging at the University of Saskatchewan. Dr. Babyn's current research interests include applications of artificial intelligence within medical imaging and the imaging of Hemophilia. He has made significant contributions to the imaging literature with over 200 publications and other academic works to date.

Samantha C. Gouw, MD, PhD is trained as a pediatric hematologist and clinical epidemiologist. She received her PhD doctorate on the etiology of inhibitor development in children with severe hemophilia A at Utrecht University in 2011. In collaboration with a team of international colleagues, she published several papers in Blood and New England Journal of Medicine on genetic and non-genetic risk factors of inhibitor development. She currently works as a clinician-researcher at the Department of Pediatric Hematology at the Amsterdam University Medical Center. She is the coordinating researcher of a nationwide study and biobank in hemophilia patients at the Department of Clinical Epidemiology at Leiden University Medical center, The Netherlands and is a work package leader in the National Symphony Consortium. Her current research focuses on inhibitor development and immune tolerance induction and the quality of hemophilia care, especially e-health and value based health care.

Maria Elisa Mancuso (MD, PhD) is an Hematologist and works as a Senior Hematology Consultant at the Center for Thrombosis and Hemorrhagic Diseases of IRCCS Humanitas Research Hospital in Rozzano, Milan, Italy. She is Adjunct Clinical Professor at Humanitas University. She obtained a post-degree in Clinical and Experimental Hematology and a PhD in Clinical Methodology. She is involved in clinical research and has published several original articles in peer-reviewed journals as The Lancet, Blood, Journal of Thrombosis and Haemostasis, Haematologica, Thrombosis and Haemostasis, British Journal of Haematology and Haemophilia. She is reviewer for several peer- reviewed journals and member of the Editorial Board of JTH. She is a member of several scientific societies (ISTH, WFH, ASH, EAHAD, SISET, AICE, EHA) and she is involved as medical member in the Extremely Rare & Inhibitor (ERIN) Working Group of the European Hemophilia Consortium (EHC). She is the Chair of the Medical Advisory Group of the EHC and vice-president of the Italian Association of Hemophilia Centers (AICE). She has acted as co-chair of the Scientific and Standardization Subcommittee of ISTH on FVIII, FIX and rare bleeding disorders. She has been involved as principal and co-investigator in several clinical trials, and she takes care of both children and adults with hemophilia and other congenital bleeding disorders with a specific scientific interest in novel therapies, prophylaxis, synovitis and treatment individualization.